Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 18

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 18
---
 PCT applications, we filed national phase applications in member states of the EPO, in PRC and 12 other
jurisdictions. The claimed inventions are described as: “Compounds Affecting Pigment Production and Methods for Treatment of Bacterial
Diseases.”

Acticule has the right to grant
sublicenses to third parties under the license agreements without prior approval from Versitech Limited and to assign the agreements to
any successor to the business related to the licenses. In the event that Acticule makes an improvement to the licensed technologies, so
long as the improvement does not incorporate any licensed patents, Acticule will be the owner to such improvement, subject to a non-exclusive
royalty-free license being granted back to Versitech Limited for academic and research purposes only.

The exclusive license agreements
shall be in effect until the expiration of all licensed patents (please refer to the patent expiration dates under “Intellectual
Property”). Acticule may terminate the licenses at any time with 6-month written notice in advance. Either party may terminate the
agreements upon a material breach by other party.

SACT-1: A Repurposed Drug for the Treatment of Neuroblastoma

Drug repurposing is a strategy
for identifying new indications for approved or investigational drugs that are outside the scope of the original medical uses. It is often
viewed as a lower-cost method for drug commercialization, as it is based on already-approved drugs (which has been proven to be safe for
human use by the respective governing regulatory agency) and explores new target indications. (Ashburn, T. T. & Thor, K. B.
Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673 – 683, 2004).

<div align='center'>S-9</div>

One of the advantages of drug repurposing is a lower development risk due to safety and toxicity, as well as other properties related to water solubility, absorption, distribution and metabolism, as the safety and CMC profiles of marketed drugs are usually well-established. Due to the same reason, the development time is also shortened because there is no need to repeat the whole spectrum of the safety assessment. As a result, the drug repurposing approach appears to be attractive due to its superior risk management, smaller capital investment and quicker financial return. (Sudeep Pushpakom, et. al. Drug repurposing: